Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial

Sci Rep. 2021 Jul 22;11(1):14971. doi: 10.1038/s41598-021-94574-x.

Abstract

Given that nonadherence is related to subject characteristics and drug tolerance and preserved eye drops tend to be more intolerable than preservative-free ones, we conducted a phase 4, parallel-grouped, investigator-blind, active-control, randomized, multicenter study. A total of 51 patients with intraocular pressure (IOP) ≥ 15 mmHg diagnosed with open-angle glaucoma or ocular hypertension were randomly assigned to the preserved latanoprost group (n = 26) and the preservative-free latanoprost group (n = 25). The efficacy variables were corneal/conjunctival staining grade, Ocular Surface Disease Index (OSDI), adherence at 12 weeks after the first administration; corneal/conjunctival staining grade at 4 weeks; and IOP, tear break-up time (TBUT), and hyperemia score at 4 and 12 weeks. The safety variables included visual acuity and drug tolerance questionnaire results. There was no statistically significant difference in corneal/conjunctival staining grade, OSDI, or TBUT between the groups at 4 and 12 weeks. However, the adherence rate was higher and the hyperemia score was lower in the preservative-free group than in the preserved group. The severity and duration of stinging/burning sensation were lower in the preservative-free group than in the preserved group. Overall, preservative-free latanoprost showed better ocular tolerance assessed by hyperemia scores and stinging/burning symptoms following higher adherence than preserved latanoprost.

Publication types

  • Clinical Trial, Phase IV
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Drug Administration Schedule
  • Female
  • Glaucoma, Open-Angle / drug therapy*
  • Humans
  • Intention to Treat Analysis
  • Latanoprost / administration & dosage*
  • Latanoprost / chemistry
  • Latanoprost / pharmacology
  • Male
  • Middle Aged
  • Ocular Hypertension / drug therapy*
  • Ophthalmic Solutions / administration & dosage*
  • Ophthalmic Solutions / chemistry
  • Ophthalmic Solutions / pharmacology
  • Preservatives, Pharmaceutical / chemistry
  • Treatment Adherence and Compliance
  • Treatment Outcome

Substances

  • Ophthalmic Solutions
  • Preservatives, Pharmaceutical
  • Latanoprost